Highlights Satellos Bioscience Inc.

Equities

MSCL

CA80401L3083

Delayed Toronto S.E. Other stock markets 09:58:21 2024-04-29 am EDT			5-day change	1st Jan Change
0.495 ^CAD	+3.12%		+3.12%	+15.12%

Mar. 27	Satellos Bioscience Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 27	Satellos Bioscience Announces FY 2023 Results	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Satellos Bioscience Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
Satellos Bioscience Announces FY 2023 Results	Mar. 27	MT
Satellos Presents Positive Preclinical Efficacy Data for SAT-3247 at the 2024 MDA Clinical & Scientific Conference	Mar. 04	CI
Satellos Bioscience Inc. Brief: Says Will commence trading on the Toronto Stock Exchange as of the opening of trading tomorrow	Feb. 14	MT
Satellos Bioscience Inc. Announces Promising Preliminary Data in Facioscapulohumeral Muscular Dystrophy	Feb. 13	CI
Satellos Bioscience Inc. Brief: Shares Jumped 13.4% on Monday; Co Recently Received Conditional Approval to Graduate to the Toronto Stock Exchange	Jan. 23	MT
Satellos Bioscience Inc. Brief: Announced Earlier Tuesday Management Team Update; Alan K. Jacobs, Chief Medical Officer Has Left to Pursue Other Opportunities; Jordan Dubow Engaged As Chief Medical Advisor	Jan. 23	MT
Satellos Bioscience Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 22	CI
Satellos Bioscience Announces 2023 Q3 Financial Results and Operational Highlights	Nov. 22	MT
Satellos Biosciences Provides Update on Duchenne Muscular Dystrophy Program	Nov. 14	MT
Satellos Bioscience Inc. Discloses Drug Target and Provides Development Update on Duchenne Muscular Dystrophy Program	Nov. 14	CI
Satellos Bioscience Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-27	CI
Satellos Bioscience Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-30	CI
Satellos Bioscience Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-29	CI
Satellos Bioscience Inc. Announces Additional Results from Further Preclinical Studies Using Its Lead Drug Candidate SAT-3153	23-03-10	CI
Satellos Bioscience Inc Announces Results from Multiple Preclinical Studies in A Disease Model of Duchenne Muscular Dystrophy	23-02-06	CI
Satellos Bioscience Announces Development Candidate	23-01-03	CI
Satellos Bioscience Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-23	CI
Satellos Bioscience Inc. Creates Prioritized and Advanced Novel Small Molecule Drug Candidates into Further Preclinical Studies	22-11-03	CI
Satellos Bioscience Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-29	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Satellos Bioscience Inc.

Equities

MSCL

CA80401L3083

Highlights

Filters